Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir's Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including DeltaBusiness Wire • 09/29/21
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare ConferenceBusiness Wire • 09/07/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Avalara, Inc. - ALVRNewsfile Corp • 08/26/21
AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare ConferenceBusiness Wire • 02/17/21
AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital ExperienceBusiness Wire • 02/11/21
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital ExperienceBusiness Wire • 01/11/21
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory VirusesBusiness Wire • 12/17/20
Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual MeetingBusiness Wire • 12/07/20
Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell TherapyBusiness Wire • 12/05/20
AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare ConferenceBusiness Wire • 11/24/20
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual MeetingGlobeNewsWire • 11/04/20
Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation RecipientsGlobeNewsWire • 10/21/20
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of High-Risk COVID-19 PatientsGlobeNewsWire • 09/17/20
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety OfficerGlobeNewsWire • 09/08/20
AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare ConferenceGlobeNewsWire • 08/25/20